Status:
TERMINATED
RescuE pLAsma eXchange in Severe COVID-19
Lead Sponsor:
Heidelberg University
Conditions:
Therapeutic Plasma Exchange
Covid19
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
The spectrum of coronavirus disease 2019 (COVID-19) ranges from asymptomatic infection to acute respiratory distress syndrome ("ARDS") and patient death. Severely affected patients may develop a cytok...
Eligibility Criteria
Inclusion
- Written informed consent by the study participant or their legally appointed representative.
- Age ≥ 18 years
- Evidence of acute SARS-CoV-2 infection, confirmed by PCR testing
- Invasive ventilation
- Fever ≥ 38.5°C, confirmed by a total of 3 consecutive measurements or ongoing renal replacement therapy and temperature ≥ 37.5°C
- D-dimers ≥ 2mg/L
- Dexamethasone ≥ 6mg/day or equivalent dose on at least 2 days
Exclusion
- Age \> 85 years
- Pre-existing treatment limitations
- Pregnancy
- Confirmed pulmonary arterial embolism with hemodynamically relevant right heart strain
- ST-segment elevation myocardial infarction (STEMI)
- Participation in an intervention study elsewhere
Key Trial Info
Start Date :
January 7 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2023
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT04685655
Start Date
January 7 2020
End Date
April 30 2023
Last Update
April 15 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Heidelberg University Hospital
Heidelberg, Baden-Wurttemberg, Germany, 69120
2
Klinikum Stuttgart
Stuttgart, Baden-Wurttemberg, Germany, 70174
3
University Hospital Essen
Essen, North Rhine-Westphalia, Germany, 45147